Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prestin (Solute carrier family 26 member 5; SLC26A5) is a transmembrane voltage-sensitive motor protein expressed exclusively in the basolateral plasma membrane of outer hair cells of the mammalian cochlea[6][4][1]. It converts changes in membrane potential into rapid mechanical force, driving the somatic electromotility that underpins cochlear amplification and frequency selectivity—essential for sensitive hearing in mammals[6][4][1][5]. Structurally, Prestin belongs to the SLC26/SulP family of anion exchangers, is organized as a dimer, and contains 14 transmembrane segments plus a C-terminal STAS (sulfate transporter and anti-sigma factor antagonist) domain[2][3]. Unlike related family members, Prestin serves a unique piezoelectric-like motor function rather than canonical anion transport[2][4]. Mutations in SLC26A5 are associated with nonsyndromic hearing loss (DFNB61) via impaired electromotility and OHC degeneration[1][4][5]. Prestin’s function and regulation depend on membrane cholesterol, protein interactions, intracellular calcium, and alternative splicing. No approved drugs specifically target Prestin, though its pivotal role in hearing continues to motivate therapeutic and biomarker research[1][4][6][2].
Ototoxic agents may block or modulate Prestin function by disturbing cholesterol interaction, cytoskeletal contacts, or anion binding. Salicylate can reduce Prestin-driven electromotility through direct interaction or possibly by modulating Prestin’s voltage dependence.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 26 member 5 (SLC26A5).